Therapeutic drug monitoring informs asparaginase dose scheduling in the InPOG-ALL-15-01-ICiCLe-ALL-14 trial
Main Authors: | Jasmeet Sidhu, Debparna Saha, Prakriti Roy, Meghna Banerjee, Pritha Paul, Samik Samaddar, Arindam Basu, Vaskar Saha, Shekhar Krishan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-01-01
|
Series: | Pediatric Hematology Oncology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468124517302899 |
Similar Items
-
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India
by: Nandana Das, et al.
Published: (2022-01-01) -
Indian Pediatric Oncology Group (InPOG) – Collaborative research in India comes of age
by: Ramandeep Singh Arora, et al.
Published: (2016-05-01) -
Evolving strategies in the management of relapsed acute lymphoblastic leukaemia – TMCKidsALLR1
by: Prakriti Roy, et al.
Published: (2017-01-01) -
Distinct heterogeneity in Indian patients with high hyperdiploid precursor B cell all identified by high density array analysis
by: Mayur Parihar, et al.
Published: (2017-01-01) -
Outcomes of COVID-19 in children with cancer – Report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India
by: Revathi Raj, et al.
Published: (2022-06-01)